Chronic Rhinosinusitis Trial, Terminated NCT01214057 Sponsor: The University of Texas Health Science Center, Houston Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial involved 23 people who were having nasal/sinus surgery. Participants were split into two groups: 12 received total intravenous anaesthesia (all anaesthetic drugs given through a drip) and 11 received inhaled anaesthesia (anaesthetic gases breathed in). The trial was measuring several things during surgery, including how much blood was lost, how clearly the surgeon could see the operating area, how well the blood was clotting (specifically how platelets — the cells that help blood clot — were functioning), and how much blood was flowing through the nasal lining. The reported data shows that the intravenous anaesthesia group had a measured blood loss of around 153 millilitres on average, while the inhaled anaesthesia group had a measured blood loss of around 356 millilitres on average. For surgical field visibility, surgeons used a rating scale from 0 (no bleeding at all) to 5 (so much bleeding that surgery is usually not possible) — the reported data shows that no participants in either group received the most severe rating of 5. For platelet (clotting cell) function, higher numbers indicate stronger clotting; the reported measurements across different time points ranged from about 58 to 71 mm in the intravenous group and from about 43 to 69 mm in the inhaled group. For nasal blood flow, more negative numbers indicate greater blood flow to the nasal lining; the reported data shows the inhaled anaesthesia group had more negative readings (ranging down to −0.41) compared to the intravenous group (ranging down to −0.11). These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Chronic Rhinosinusitis Trial, Terminated

NCT01214057
Terminated Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed by a doctor with chronic rhinosinusitis (long-term inflammation or infection of the sinuses)
  • A surgeon has determined that you need endoscopic sinus surgery (a procedure to look inside and treat the sinuses using a small camera)

Who may not be able to join:

  • You are currently pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Terminated
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 May 2010
Est. completion
1 October 2012

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Volume of Blood Loss; Number of Participants for Whom Surgical Field Visualization Was Deemed Severely Compromised; Platelet Function as Assessed by Thromboelastography (TEG) Platelet Mapping (PM); Platelet Function as Assessed by Thromboelastography (TEG) Platelet Mapping (PM); Nasal Blood Flow to the Sinonasal Mucosa as Assessed by the Rhinolux System; Nasal Blood Flow to the Sinonasal Mucosa as Assessed by the Rhinolux System

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov